Home
Covid-19
Tools
Introduction to the Tools
Model Government Use Licences
Model Uses of Paragraph 7 or “LDC Waiver”
Special Compulsory Licences for Export of Medicines
Options for Regional Economic Communities
Voluntary Licences
TRIPS Flexibilities Database
Resources
Briefs & Briefing Documents
Publications
Tools
Useful Links
All Resources
Blog
About
Sign in
Welcome!
Log into your account
your username
your password
Forgot your password?
Password recovery
Recover your password
your email
Search
Medicines Law & Policy
Research and resources on intellectual property and health
Home
Covid-19
Tools
Introduction to the Tools
Model Government Use Licences
Model Uses of Paragraph 7 or “LDC Waiver”
Special Compulsory Licences for Export of Medicines
Options for Regional Economic Communities
Voluntary Licences
TRIPS Flexibilities Database
Resources
Briefs & Briefing Documents
Publications
Tools
Useful Links
All Resources
Blog
About
Pascale Boulet
5 POSTS
0 COMMENTS
Are gene-editing therapies patentable? A WIPO side event investigates.
Pascale Boulet
-
December 11, 2018
CJEU Ruling on Truvada recalls ‘evergreening’ goes against public health interests
Pascale Boulet
-
September 10, 2018
How patents, data exclusivity and SPCs interact to extend market exclusivity of medicines: the...
Pascale Boulet
-
July 10, 2018
Will the European Court of Justice put a stop to the evergreening of Truvada...
Pascale Boulet
-
May 8, 2018
Modifier la législation européenne pour mettre en œuvre la licence d’office en France
Pascale Boulet
-
November 14, 2017
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.
Ok
This work is licensed under Creative Commons.